Stock Movers

iHeartPodcasts
  • 0.0 (0)
  • Business News
  • Updated daily

Listen for five-minute conversations on today's biggest winners and losers in the stock market.  Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

  1. 3 hr ago

    SK Hynix Rises, Moderna Gains, Estee Lauder Soars as Results Show Turnaround Gaining Steam

    On this episode of Stock Movers: -SK Hynix ADRs rose. SK Hynix Inc. unveiled plans to buy back 40 trillion won ($29 billion) of shares and return more profits to investors, moving to stabilize its shares after they fell more than 50% in two months. The memory chipmaker said it will buy back as many as 24 million shares between Aug. 20 and Nov. 19 and cancel them, according to a regulatory filing Wednesday. It also raised its shareholder return pledge to more than 50% of cumulative free cash flow from 2025 to 2027, equivalent to about $170 billion, according to Bloomberg calculations.  -Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027. -Estee Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and organic sales growth accelerated to 5%. The company reaffirmed guidance for organic net sales growth of 3% to 5% in its current fiscal year, and raised guidance on its adjusted operating margin. See omnystudio.com/listener for privacy information.

  2. 5 hr ago

    Moderna Rises, La-Z Boy Drops, Norfolk Southern Corp Climbs as Regulator Resumes Review of Bid From Rival

    On this episode of Stock Movers:- Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027.- La-Z Boy (LZB) shares tumble after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate. KeyBanc Capital Markets analyst Bradley Thomas says the company “issued F2Q sales and implied EPS guidance below consensus, pressured in part by continued investments”- Norfolk Southern Corp (NSC) climbs after a federal regulator resumed its review of Union Pacific’s bid for the rival. The Surface Transportation Board established a procedural schedule for public comment, with participants having until Sept. 4 to file a notice of intent to participate in the review process. See omnystudio.com/listener for privacy information.

  3. 5 hr ago

    Moderna's Record Surge, Estee Lauder Rises on Q4 Beat, La-Z-Boy Sinks

    Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock’s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.’s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (EL) rallied after the beauty company’s adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views. - Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate. See omnystudio.com/listener for privacy information.

  4. 8 hr ago

    Target Posts Comp Sales Beat, Lowe's Slips on Outlook, Moderna Soars on Melanoma Study

    Today's biggest winners and losers in the stock market.On this episode of Stock Movers:- Shares of Target Corp. (TGT) dipped in the early session. That's despite the retail giant reported comparable sales for the second quarter that beat the average analyst estimate. The company also lifted its full-year guidance after results outpaced estimates in the latest quarter, suggesting the big-box retailer is moving past a lengthy sales slump. The company now expects net sales to increase about 5% in the current fiscal year, which ends in early 2027 — a percentage point higher than the previous guidance.- Shares of Lowe's Cos. (LOW) slipped in premarket trading after the company cut its outlook for the full year after posting results that missed Wall Street estimates, showing how a stubbornly weak housing market is eroding the home-improvement retailer’s performance. The company now expects comparable sales to be flat this fiscal year, after previously forecasting as much as 2% growth. Comparable sales, which measure results at locations open at least a year, grew 0.2% in the second quarter, missing the average of estimates compiled by Bloomberg.- Shares of Moderna (MRNA) surged as much as 80% in premarket trading  after the company joined Merck (MRK) to announce their personalized cancer vaccine helped cut the recurrence of melanoma in a large, late-stage trial - an important milestone for the mRNA-based therapy. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, could lower the rate of melanoma recurrence, compared with the immunotherapy alone. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. See omnystudio.com/listener for privacy information.

  5. 10 hr ago

    Trainline Dips, Smith & Nephew Falls, Straumann Drops

    Today's biggest winners and losers in the stock market.On this episode of Stock Movers:- Trainline shares fell as much as 17%, the most in five years, after the UK competition watchdog opened an investigation into whether the rail-booking platform breached consumer law through “drip pricing.”- Smith & Nephew shares drop to the lowest intraday level since May 12 after the medical devices maker said chief financial officer John Rogers will leave his position at the end of next month. Analysts suggest his departure will raise questions about the company’s outlook.- Straumann drops as much as 9.1%, the most in a year, after the Swiss dental implant maker said Christopher Norbye would replace Guillaume Daniellot as CEO. Analysts at Bernstein and JPMorgan said Daniellot was “well-liked,” with the news overshadowing the better-than-expected earnings for the first half-year. See omnystudio.com/listener for privacy information.

  6. 11 hr ago

    Carlsberg Dips, Frontline Rises, Smith & Nephew Drops

    Today's biggest winners and losers in the stock market.On this episode of Stock Movers:- Carlsberg volume growth was softer than expected in the first half, as subdued beer demand in Europe and Asia undermined a strong performance in soft drinks.- Shares in Frontline PLC which owns a fleet of large crude carriers are benefiting from elevated crude tanker rates due to uncertainty in the Strait of Hormuz. - Smith & Nephew shares drop as much as 3.7% to the lowest intraday level since May 12 after the medical devices maker said chief financial officer John Rogers will leave his position at the end of next month. Analysts suggest his departure will raise questions about the company’s outlook. See omnystudio.com/listener for privacy information.

  7. 13 hr ago

    Unitree Surges, Baidu Plummets, Xiaomi Rises

    On this episode of Stock Movers:- Unitree Robotics shares opened 629% higher in their Shanghai trading debut after raising 6.1 billion yuan ($904 million) in an initial public offering that will make it the first publicly traded humanoid robot maker in mainland China.- Baidu shares slumped as much as 14.4% in Hong Kong, putting it on track for its worst day since 2022, after the Chinese search-engine operator’s revenue missed estimates and AI capex soared. - Xiaomi shares rise as much as 5% in Hong Kong after it reported smartphone revenue that was better than feared despite a global industry downturn. Its EV unit came under pressure from intense competition in China with Bernstein analysts saying management has lowered its full year EV sales target to 450,000 units. See omnystudio.com/listener for privacy information.

  8. 21 hr ago

    Targa Resources Rises, Meta Drops on Lawsuit, Duolingo Gains

    On this episode of Stock Movers: - Targa Resources (TRGP) shares rose as much as 9.8% to a record high after the energy company signed new 20-year, fee-based integrated midstream agreements with ExxonMobil subsidiaries covering gathering, processing, NGL transportation, and fractionation across the Permian Basin through 2046. Targa also announced a new 70-mile expansion of its planned Bull Run natural gas pipeline network in the Permian Basin region. - Meta Platforms (META) is being sued by 29 states for allegedly deceiving the public by targeting children on Facebook and Instagram with technology designed to turn them into compulsive users and drive up advertising revenue. The states allege that Meta knowingly designed features that encouraged compulsive and prolonged use of its platforms by young people, while simultaneously misleading consumers about safety features on its platforms. - Duolingo (DUOL) shares are up after D.A. Davidson upgraded the language learning platform to buy from neutral citing a “turning point” in acceleration of daily active user metrics. See omnystudio.com/listener for privacy information.

See All (2k)

Hosts & Guests

About

Listen for five-minute conversations on today's biggest winners and losers in the stock market.  Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Information

  • Creator
    iHeartPodcasts
  • Years Active
    2025 - 2026
  • Episodes
    2k
  • Rating
    Clean
  • Copyright
    2026 iHeartMedia, Inc. © Any use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from iHeartMedia
  • Show Website
    Stock Movers